Literature DB >> 2246018

Cell mediated immunity in childhood malaria.

S Rajajee1, V Pushpa, P R Narayanan.   

Abstract

Children with malarial infection, due to P. Vivax and P. falciparum, were tested for cell mediated immunity (CMI) by lymphocyte proliferative response to mitogens PHA (phytohaemagglutinin) and PWM (poke weed mitogen) and antigen PPD (purified protein derivative). This was done during the period of parasitemia and after treatment, and compared to 19 normal matched controls. There was no significant difference between the patients and the control group with regard to PHA (patients 57.4 +/- 50.5; controls 61.3 +/- 54.9); PWM (patients 27.4 +/- 19.9, controls 29.9 +/- 24.5); PPD (patients 2.2 +/- 1.2, controls 1.9 +/- 1.4). There was also no significant difference in the lymphocyte responses during the period of parasitemia and after treatment. Hence, there does not seem to be any depression of CMI as shown by lymphocyte proliferative responses during childhood malaria.

Entities:  

Mesh:

Year:  1990        PMID: 2246018     DOI: 10.1007/bf02722090

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  4 in total

1.  T-cell activation in murine malaria.

Authors:  A N Jayawardena; G A Targett; E Leuchars; R L Carter; M J Doenhoff; A J Davies
Journal:  Nature       Date:  1975-11-13       Impact factor: 49.962

2.  Enhanced Trypanosoma musculi infections in mice with concomitant malaria.

Authors:  F E Cox
Journal:  Nature       Date:  1975-11-13       Impact factor: 49.962

3.  Immune response in malnourished children with measles.

Authors:  P Bhaskaram; J Madhusudhan; K V Radhakrishna; V Reddy
Journal:  J Trop Pediatr       Date:  1986-06       Impact factor: 1.165

4.  Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors.

Authors:  M Troye-Blomberg; P Romero; M E Patarroyo; A Björkman; P Perlmann
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.